» Authors » Zahra Rattray

Zahra Rattray

Explore the profile of Zahra Rattray including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 31
Citations 191
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Armstrong G, Shah V, Sanches P, Patel M, Casey R, Jamieson C, et al.
Comput Struct Biotechnol J . 2024 Jun; 23:2345-2357. PMID: 38867721
The formulation of high-concentration monoclonal antibody (mAb) solutions in low dose volumes for autoinjector devices poses challenges in manufacturability and patient administration due to elevated solution viscosity. Often many therapeutically...
12.
van den Driest L, Kelly P, Marshall A, Johnson C, Lasky-Su J, Lannigan A, et al.
Comput Struct Biotechnol J . 2024 May; 23:2200-2210. PMID: 38817965
Breast cancer is a multifaceted disease and a leading cause of cancer morbidity and mortality in females across the globe. In 2020 alone, 2.3 million women were diagnosed and 685,000...
13.
Al Sultan A, Rattray Z, Rattray N
J Appl Toxicol . 2024 Apr; 44(8):1214-1235. PMID: 38654465
Thiazolidinediones (TZDs) (e.g. pioglitazone and rosiglitazone), known insulin sensitiser agents for type II diabetes mellitus, exhibit controversial effects on cardiac tissue. Despite consensus on their association with increased heart failure...
14.
Binici B, Rattray Z, Schroeder A, Perrie Y
Vaccines (Basel) . 2024 Mar; 12(3). PMID: 38543916
In this study, we consider the influence of biological sex-specific immune responses on the assessment of mRNA vaccines in pre-clinical murine studies. Recognising the established disparities in immune function attributed...
15.
Al Sultan A, Rattray Z, Rattray N
Metabolomics . 2024 Feb; 20(2):24. PMID: 38393619
Introduction: Thiazolidinediones (TZDs), represented by pioglitazone and rosiglitazone, are a class of cost-effective oral antidiabetic agents posing a marginal hypoglycaemia risk. Nevertheless, observations of heart failure have hindered the clinical...
16.
Daramy K, Punnabhum P, Hussain M, Minelli C, Pei Y, Rattray N, et al.
J Pharm Sci . 2024 Jan; 113(9):2826-2836. PMID: 38163549
Nanoparticles are increasingly implemented in biomedical applications, including the diagnosis and treatment of disease. When exposed to complex biological media, nanoparticles spontaneously interact with their surrounding environment, leading to the...
17.
Kelly P, Ng H, Farrell G, Mckirdy S, Russell R, Hansen R, et al.
Metabolites . 2022 Nov; 12(11). PMID: 36422250
Liquid chromatography coupled with mass spectrometry (LC-MS) metabolomic approaches are widely used to investigate underlying pathogenesis of gastrointestinal disease and mechanism of action of treatments. However, there is an unmet...
18.
Cai Y, Shen X, Lu L, Yan H, Huang H, Gaule P, et al.
Biol Sex Differ . 2022 Oct; 13(1):61. PMID: 36274154
Background: Bile acids are known to be genotoxic and contribute to colorectal cancer (CRC). However, the link between CRC tumor bile acids to tumor location, patient sex, microbiome, immune-regulatory cells,...
19.
Abdullah M, Zeng R, Margerum C, Papadopoli D, Monnin C, Punter K, et al.
Cell Rep . 2022 Aug; 40(7):111198. PMID: 35977476
The relationship between nutrient starvation and mitochondrial dynamics is poorly understood. We find that cells facing amino acid starvation display clear mitochondrial fusion as a means to evade mitophagy. Surprisingly,...
20.
Berardi D, Hunter Y, van den Driest L, Farrell G, Rattray N, Rattray Z
Cancers (Basel) . 2022 Aug; 14(15). PMID: 35954325
Metabolic reprogramming and genomic instability are key hallmarks of cancer, the combined analysis of which has gained recent popularity. Given the emerging evidence indicating the role of oncometabolites in DNA...